Belpointe Asset Management LLC raised its position in AstraZeneca plc (NYSE:AZN) by 22.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 11,207 shares of the company’s stock after purchasing an additional 2,090 shares during the quarter. Belpointe Asset Management LLC’s holdings in AstraZeneca were worth $389,000 as of its most recent SEC filing.
A number of other large investors have also recently bought and sold shares of the business. Fisher Asset Management LLC boosted its holdings in AstraZeneca by 2.7% in the 4th quarter. Fisher Asset Management LLC now owns 11,917,332 shares of the company’s stock valued at $413,531,000 after purchasing an additional 315,759 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in AstraZeneca by 7.6% in the 3rd quarter. Wells Fargo & Company MN now owns 4,406,824 shares of the company’s stock valued at $149,303,000 after purchasing an additional 310,389 shares during the last quarter. Farallon Capital Management LLC boosted its holdings in AstraZeneca by 18.4% in the 4th quarter. Farallon Capital Management LLC now owns 3,765,000 shares of the company’s stock valued at $130,646,000 after purchasing an additional 585,000 shares during the last quarter. Ameriprise Financial Inc. boosted its holdings in AstraZeneca by 7.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 3,026,781 shares of the company’s stock valued at $102,643,000 after purchasing an additional 199,519 shares during the last quarter. Finally, Capital Bank & Trust Co boosted its holdings in AstraZeneca by 2.1% in the 3rd quarter. Capital Bank & Trust Co now owns 2,730,208 shares of the company’s stock valued at $92,499,000 after purchasing an additional 57,353 shares during the last quarter. Institutional investors own 15.15% of the company’s stock.
Several research firms have weighed in on AZN. Leerink Swann boosted their target price on shares of AstraZeneca from $36.00 to $38.00 and gave the company a “market perform” rating in a report on Tuesday, February 6th. Sanford C. Bernstein boosted their target price on shares of AstraZeneca from $40.00 to $42.00 and gave the company an “outperform” rating in a report on Monday, February 5th. ValuEngine lowered shares of AstraZeneca from a “strong-buy” rating to a “buy” rating in a report on Wednesday, March 7th. Zacks Investment Research raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Monday, January 22nd. Finally, BMO Capital Markets reissued a “buy” rating and issued a $38.00 price target on shares of AstraZeneca in a research note on Friday, January 26th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $36.26.
Shares of AstraZeneca plc (NYSE AZN) opened at $34.59 on Friday. AstraZeneca plc has a 52 week low of $28.43 and a 52 week high of $36.70. The firm has a market cap of $85,662.54, a P/E ratio of 14.59, a P/E/G ratio of 2.02 and a beta of 0.71. The company has a current ratio of 0.80, a quick ratio of 0.62 and a debt-to-equity ratio of 0.93.
AstraZeneca (NYSE:AZN) last announced its earnings results on Friday, February 2nd. The company reported $1.30 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.86. AstraZeneca had a net margin of 13.36% and a return on equity of 34.74%. The firm had revenue of $5.78 billion for the quarter, compared to the consensus estimate of $5.49 billion. During the same period in the prior year, the firm earned $1.21 EPS. The firm’s revenue for the quarter was up 3.4% on a year-over-year basis. analysts predict that AstraZeneca plc will post 1.69 earnings per share for the current year.
The firm also recently announced a semiannual dividend, which will be paid on Monday, March 19th. Investors of record on Friday, February 16th will be paid a dividend of $0.95 per share. This represents a yield of 5.62%. The ex-dividend date is Thursday, February 15th. AstraZeneca’s payout ratio is currently 57.81%.
TRADEMARK VIOLATION WARNING: This article was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://ledgergazette.com/2018/03/18/astrazeneca-plc-azn-holdings-boosted-by-belpointe-asset-management-llc.html.
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.